Especializado en DIABETES, EDUCACIÓN DIABETOLÓGICA y MEDICINA INTERNA
Aquí encontrarás temas relacionados a la medicina del adulto y otros temas interesantes
miércoles, 14 de enero de 2015
Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multi-centre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension Diabetes, Obesity and Metabolism, 01/12/2015 Clinical Article
Jin SM, et al. – The authors aimed to compare the efficacy and safety of lobeglitazone and pioglitazone as add–ons to metformin in patients with type 2 diabetes. Lobeglitazone was not inferior to pioglitazone as an add–on to metformin in terms of the efficacy and safety.
Patients who were inadequately controlled by metformin were randomized and treated once daily with either lobeglitazone (0.5 mg, n = 128) or pioglitazone (15 mg, n=125) for 24 weeks, with a 28-week extension of lobeglitazone treatment in patients who consented.
The primary endpoint was the change in HbA1c level between baseline and week 24.
At week 24, the mean change from baseline HbA1c was -0.74% for the lobeglitazone group and -0.74% for the pioglitazone group, with a mean difference of 0.01% [95% confidence interval (CI) of difference, -0.16 to 0.18].